Literature DB >> 7906734

Effects of the selective dopaminergic D2 agonist quinelorane on the activity of dopaminergic and noradrenergic neurons projecting to the diencephalon of the rat.

M J Eaton1, K J Lookingland, K E Moore.   

Abstract

The purpose of the present study was to characterize dopaminergic D2 receptor-mediated regulation of catecholaminergic neurons in the diencephalon by examining the acute effects of the potent and selective D2 agonist quinelorane (LY163502; trans-(-)-5,5a,6,7,8,9,9a,10-octahydro-6-propylpyrimido [4,5-g] quinolin-2-amine dihydrochloride dihydrate) on concentrations of 3,4-dihydroxyphenylacetic acid, dopamine, 3-methoxy-4-hydroxyphenylethyleneglycol and norepinephrine in the dorsomedial nucleus of the hypothalamus and horizontal limb of the diagonal band of Broca of intact and norepinephrine-depleted male rats. For comparative purposes, various other diencephalic brain regions and the nucleus accumbens were also examined. The results of this study reveal that quinelorane decreases the activity of dopaminergic neurons in the nucleus accumbens, horizontal limb of the diagonal band of Broca and dorsomedial nucleus of the hypothalamus, whereas it increases the activity of noradrenergic neurons projecting to the dorsomedial nucleus of the hypothalamus, but not the horizontal limb of the diagonal band of Broca. These inhibitory and stimulatory actions of quinelorane are blocked by or reverse the effects of the D2-selective antagonist raclopride, indicating that quinelorane is acting at D2 receptors. Taken together, these results indicate that quinelorane inhibits DA neurons within the diencephalon, whereas it activates a subpopulation of noradrenergic neurons projecting to this brain region.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7906734

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Enhanced humoral immunity in mice lacking CB1 and CB2 receptors (Cnr1-/-/Cnr2-/- mice) is not due to increased splenic noradrenergic neuronal activity.

Authors:  Tyrell Simkins; Robert B Crawford; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-29       Impact factor: 4.147

2.  D2-like receptors in nucleus accumbens negatively modulate acetylcholine release in prefrontal cortex.

Authors:  Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropharmacology       Date:  2007-06-26       Impact factor: 5.250

3.  Reduced Noradrenergic Signaling in the Spleen Capsule in the Absence of CB1 and CB2 Cannabinoid Receptors.

Authors:  Tyrell J Simkins; David Fried; Kevin Parikh; James J Galligan; John L Goudreau; Keith J Lookingland; Barbara L F Kaplan
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-10       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.